{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:03Z","timestamp":1792431963744,"version":"4.5.0"},"reference-count":259,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,9,22]]},"DOI":"10.18632\/oncotarget.4990","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T12:51:29Z","timestamp":1443444689000},"page":"24750-24779","source":"Crossref","is-referenced-by-count":115,"title":["Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy"],"prefix":"10.18632","volume":"6","author":[{"given":"Ismael","family":"Riquelme","sequence":"first","affiliation":[{"name":"Department of Pathology, School of Medicine, Universidad de La Frontera, CEGIN-BIOREN, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Universidad de La Frontera, CEGIN-BIOREN, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime A.","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Universidad de La Frontera, CEGIN-BIOREN, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Nervi","sequence":"additional","affiliation":[{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Department of Hematology Oncology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Millennium Institute on Immunology and Immunotherapy, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Garrido","sequence":"additional","affiliation":[{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Department of Hematology Oncology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro H.","family":"Corval\u00e1n","sequence":"additional","affiliation":[{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Department of Hematology Oncology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Advanced Center for Chronic Diseases (ACCDIS), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Roa","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Advanced Center for Chronic Diseases (ACCDIS), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Bizama","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"UC-Center for Investigational Oncology (CITO), Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,7,22]]},"reference":[{"issue":"2","key":"1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Forman","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1200\/JCO.2012.47.1714","article-title":"Molecular profiling of gastric cancer: toward personalized cancer medicine","volume":"31","author":"Ford","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"3","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-07-0173","article-title":"Protein expression profiling and molecular classification of gastric cancer by the tissue array method","volume":"13","author":"Kim","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7517","key":"4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"The Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"issue":"9","key":"5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrclinonc.2014.138","article-title":"Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas","volume":"11","author":"Razzak","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2005.06.026","article-title":"Gene deregulation in gastric cancer","volume":"360","author":"Otto","year":"2005","journal-title":"Gene"},{"issue":"7","key":"7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12094-012-0836-9","article-title":"SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma","volume":"14","author":"Seom","year":"2012","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.sla.0000149300.28588.23","article-title":"Gastric adenocarcinoma: review and considerations for future directions","volume":"241","author":"Hamilton","year":"2005","journal-title":"Ann Surg"},{"issue":"10","key":"9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Martenson","year":"2001","journal-title":"N Engl J Med"},{"key":"10","first-page":"pii","article-title":"Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key","author":"Goodman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Sohn","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Participants","year":"2006","journal-title":"N Engl J Med"},{"issue":"17","key":"13","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","article-title":"Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis","volume":"303","author":"Buyse","year":"2010","journal-title":"JAMA"},{"issue":"18","key":"14","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Ji","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"16","article-title":"Chemotherapy for advanced gastric cancer","author":"Fleig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/14737140.2014.915194","article-title":"Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer","volume":"14","author":"Lacave","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"McCloud","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Takagi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"1","key":"20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer","volume":"26","author":"Tsuda","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Derigs","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Norman","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Chau","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"24","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2006.10.4968","article-title":"Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group","volume":"25","author":"Group","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Bugat","year":"2008","journal-title":"Ann Oncol"},{"issue":"35","key":"26","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Fujitani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9742","key":"27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Hill","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"28","first-page":"1547","article-title":"The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen","volume":"32","author":"Bang","year":"2012","journal-title":"Anticancer Res"},{"issue":"6","key":"29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","article-title":"EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number","volume":"52","author":"Kim","year":"2008","journal-title":"Histopathology"},{"issue":"21","key":"30","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1158\/1078-0432.CCR-12-1318","article-title":"Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II\/III gastric cancer","volume":"18","author":"Sasako","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12094-011-0637-6","article-title":"Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer","volume":"13","author":"Jimeno","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"24","key":"33","first-page":"6735","article-title":"Human Gastric Carcinogenesis: A Multistep and Multifactorial Process\u2014First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention","volume":"52","author":"Correa","year":"1992","journal-title":"Cancer Res"},{"issue":"2","key":"34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/path.1868","article-title":"Helicobacter infection and gastric neoplasia","volume":"208","author":"Crabtree","year":"2006","journal-title":"J Pathol"},{"key":"35","first-page":"5164","volume-title":"World J Gastroenterol","author":"Tez","year":"2012"},{"issue":"3","key":"36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/PL00011733","article-title":"Molecular diagnosis of gastric cancer: present and future","volume":"4","author":"Yokozaki","year":"2001","journal-title":"Gastric Cancer"},{"key":"37","first-page":"327","article-title":"Genetic pathways of two types of gastric cancer","volume":"157","author":"Tahara","year":"2004","journal-title":"IARC Sci Publ"},{"issue":"5","key":"38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ng.2246","article-title":"Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes","volume":"44","author":"Huang","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"39","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/gb-2014-15-4-r55","article-title":"Genomic profile analysis of diffuse-type gastric cancers","volume":"15","author":"Kim","year":"2014","journal-title":"Genome Biol"},{"issue":"6","key":"40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ng.2984","article-title":"Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma","volume":"46","author":"Funahashi","year":"2014","journal-title":"Nat Genet"},{"key":"41","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1053\/bega.2001.0253","article-title":"Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis?","volume":"15","author":"Stolte","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-9378-7-21","article-title":"Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile","volume":"7","author":"Gulley","year":"2012","journal-title":"Infect Agent Cancer"},{"issue":"1","key":"43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010","volume":"9","author":"Hashim","year":"2014","journal-title":"Infect Agent Cancer"},{"issue":"12","key":"44","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.3390\/v4123420","article-title":"Epstein-Barr Virus (EBV)-associated Gastric Carcinoma","volume":"4","author":"Yoshiyama","year":"2012","journal-title":"Viruses"},{"issue":"2","key":"45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1349-7006.2007.00674.x","article-title":"Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features","volume":"99","author":"Eizuru","year":"2008","journal-title":"Cancer Sci"},{"issue":"2","key":"46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/gutjnl-2013-304531","article-title":"Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis","volume":"63","author":"Liao","year":"2014","journal-title":"Gut"},{"issue":"5","key":"47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920207782446160","article-title":"The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications","volume":"8","author":"Guerreiro","year":"2007","journal-title":"Curr Genomics"},{"issue":"4","key":"48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Akbani","year":"2014","journal-title":"Cell"},{"issue":"7471","key":"49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Welch","year":"2013","journal-title":"Nature"},{"issue":"5","key":"50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4161\/cbt.18943","article-title":"MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation","volume":"13","author":"Liu","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-0039.2006.00701.x","article-title":"PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies","volume":"69","author":"Zhang","year":"2007","journal-title":"Tissue Antigens"},{"issue":"5","key":"52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"Atkins","year":"2013","journal-title":"Cancer Med"},{"issue":"1","key":"53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4132\/KoreanJPathol.2013.47.1.28","article-title":"Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes","volume":"47","author":"Park do","year":"2013","journal-title":"Korean J Pathol"},{"issue":"2","key":"54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jso.23618","article-title":"Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis","volume":"110","author":"Noh","year":"2014","journal-title":"J Surg Oncol"},{"issue":"6","key":"55","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.humpath.2007.10.024","article-title":"Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival","volume":"39","author":"Ottini","year":"2008","journal-title":"Hum Pathol"},{"issue":"19","key":"56","first-page":"4420","article-title":"Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype","volume":"57","author":"Perucho","year":"1997","journal-title":"Cancer Res"},{"issue":"12","key":"57","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/MEG.0b013e3282f13cf9","article-title":"Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA","volume":"19","author":"Komel","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"58","first-page":"439","article-title":"Genetic alterations in gastric precancerous lesions","volume":"21","author":"Pirim","year":"2010","journal-title":"Genet Couns"},{"issue":"3","key":"59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1525-1578(10)60517-X","article-title":"Allelic imbalance of 8p indicates poor survival in gastric cancer","volume":"6","author":"Powell","year":"2004","journal-title":"J Mol Diagn"},{"issue":"11","key":"60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrgastro.2014.143","article-title":"Genetics of gastric cancer","volume":"11","author":"El-Omar","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ng.2983","article-title":"Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer","volume":"46","author":"Tsui","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1349-7006.2009.01163.x","article-title":"Hereditary diffuse gastric cancer: a manifestation of lost cell polarity","volume":"100","author":"Guilford","year":"2009","journal-title":"Cancer Sci"},{"issue":"12","key":"63","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/ijc.22599","article-title":"IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src\/RhoA\/ROCK signaling pathway","volume":"120","author":"Kuo","year":"2007","journal-title":"Int J Cancer"},{"issue":"8","key":"64","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/sj.bjc.6604688","article-title":"NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer","volume":"99","author":"Doran","year":"2008","journal-title":"Br J Cancer"},{"issue":"18","key":"65","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1158\/1078-0432.CCR-04-0242","article-title":"Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity","volume":"10","author":"Fan","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"66","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s13277-013-1236-7","article-title":"Expression of APC, beta-catenin and E-cadherin in Tunisian patients with gastric adenocarcinoma: clinical significance","volume":"35","author":"Mokdad-Gargouri","year":"2014","journal-title":"Tumour Biol"},{"issue":"5","key":"67","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets","volume":"61","author":"Lim","year":"2012","journal-title":"Gut"},{"issue":"4","key":"68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11523-013-0253-1","article-title":"Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors","volume":"8","author":"Kang","year":"2013","journal-title":"Target Oncol"},{"issue":"1","key":"69","first-page":"232","article-title":"Targeted therapy for gastric cancer: molecular pathways and ongoing investigations","volume":"1846","author":"Klempner","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol Res"},{"issue":"30","key":"71","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1200\/JCO.2006.07.1316","article-title":"Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127","volume":"24","author":"Abbruzzese","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"72","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.2005.03.4900","article-title":"Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients","volume":"24","author":"Giaccone","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"73","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-1970","article-title":"A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response","volume":"13","author":"Jankowski","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"74","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/annonc\/mdq604","article-title":"A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma","volume":"22","author":"Fuchs","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"75","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/annonc\/mdl459","article-title":"Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)","volume":"18","author":"Martoni","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.bjc.6604861","article-title":"Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer","volume":"100","author":"Kim","year":"2009","journal-title":"Br J Cancer"},{"issue":"2","key":"77","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s10637-009-9363-0","article-title":"A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and\/or recurrent advanced gastric cancer","volume":"29","author":"Kang","year":"2011","journal-title":"Invest New Drugs"},{"issue":"3","key":"78","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjc.6605521","article-title":"Cetuximab plus oxaliplatin\/leucovorin\/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"102","author":"Peschel","year":"2010","journal-title":"Br J Cancer"},{"issue":"6","key":"79","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Celik","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"80","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2004.05.114","article-title":"Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor","volume":"22","author":"Baselga","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"81","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s10637-012-9848-0","article-title":"Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas","volume":"31","author":"Vanhoefer","year":"2013","journal-title":"Invest New Drugs"},{"key":"82","volume-title":"Gastric Cancer: The Ghosts of Past, Present and Future","author":"Sehrish","year":"2014"},{"key":"83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12876-015-0231-4","article-title":"Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer","volume":"15","author":"Marx","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/cc.4.2.1493","article-title":"How Cancer Could be Cured by 2015","volume":"4","author":"Blagosklonny","year":"2004","journal-title":"Cell Cycle"},{"issue":"1","key":"85","first-page":"5","article-title":"Molecular therapy for gastric cancer","volume":"2","author":"Yamada","year":"2013","journal-title":"Chin Clin Oncol"},{"key":"86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/1756-0500-7-271","article-title":"Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer","volume":"7","author":"Shimada","year":"2014","journal-title":"BMC Res Notes"},{"issue":"3","key":"87","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11864-012-0192-6","article-title":"Targeted therapy for gastric cancer","volume":"13","author":"Cunningham","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"88","first-page":"62","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Claret","year":"2012","journal-title":"Front Oncol"},{"issue":"1","key":"89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"90","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bjc.2014.18","article-title":"Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)","volume":"110","author":"Furukawa","year":"2014","journal-title":"Br J Cancer"},{"key":"91","unstructured":"ClinicalTrials.gov, U.S National Institutes of Health. Available from: https:\/\/clinicaltrials.gov. Accessed December 2014."},{"issue":"19","key":"92","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study","volume":"32","author":"Chung","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"93","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013\/LOGiC","volume":"31","author":"Protsenko","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"94","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Benjamin","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"95","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13277-010-0068-y","article-title":"Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer","volume":"31","author":"Qiao","year":"2010","journal-title":"Tumour Biol"},{"issue":"13","key":"96","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3748\/wjg.v19.i13.2073","article-title":"Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"4","key":"97","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4143\/crt.2009.41.4.218","article-title":"No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer","volume":"41","author":"Yu","year":"2009","journal-title":"Cancer Res Treat"},{"issue":"6","key":"98","first-page":"2361","article-title":"Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer","volume":"30","author":"Otsuji","year":"2010","journal-title":"Anticancer Res"},{"key":"99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-9966-30-14","article-title":"Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications","volume":"30","author":"Hou","year":"2011","journal-title":"J Exp Clin Canc Res"},{"issue":"30","key":"100","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Kang","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"101","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Shah","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9911","key":"102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Topuzov","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"103","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Komatsu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"104","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Zheng","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"105","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1200\/JCO.2009.27.7988","article-title":"Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203","volume":"28","author":"Benson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"106","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Cantley","year":"2006","journal-title":"Nat Rev Genet"},{"issue":"39","key":"107","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.3748\/wjg.v16.i39.4986","article-title":"Up-regulation of PIK3CA promotes metastasis in gastric carcinoma","volume":"16","author":"Qi","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"1","key":"108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00428-014-1588-4","article-title":"The PI3K\/AKT\/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance","volume":"465","author":"Roa","year":"2014","journal-title":"Virchows Archiv"},{"issue":"3","key":"109","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/039463201202500309","article-title":"Expression of PI3K\/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis","volume":"25","author":"Li","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-008-0676-8","article-title":"Activated Akt as an indicator of prognosis in gastric cancer","volume":"453","author":"Tosi","year":"2008","journal-title":"Virchows Archiv"},{"issue":"6","key":"111","first-page":"3312","article-title":"Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas","volume":"7","author":"Kamoshida","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"14","key":"112","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1016\/j.bmc.2013.04.083","article-title":"Recent syntheses of PI3K\/Akt\/mTOR signaling pathway inhibitors","volume":"21","author":"Kulik","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"113","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1741-7015-10-161","article-title":"Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment","volume":"10","author":"Siu","year":"2012","journal-title":"BMC Med"},{"issue":"1","key":"114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/cbt.13.1.18437","article-title":"Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells","volume":"13","author":"Soong","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"13","key":"115","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1158\/0008-5472.CAN-10-4322","article-title":"Combination of PI3K\/mTOR Inhibitors: Antitumor Activity and Molecular Correlates","volume":"71","author":"Broggini","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"116","doi-asserted-by":"crossref","first-page":"e3065","DOI":"10.1371\/journal.pone.0003065","article-title":"Breast tumor vells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling","volume":"3","author":"Rosen","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1479-5876-11-241","article-title":"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere","volume":"11","author":"Yu","year":"2013","journal-title":"J Transl Med"},{"key":"118","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"Dudley","year":"2012","journal-title":"Mol Canc Ther"},{"issue":"1","key":"119","first-page":"1","article-title":"Targeting the PI3K\/AKT Pathway for the Treatment of Gastric Cancer","volume":"3","author":"Yu","year":"2014","journal-title":"Chemotherapy"},{"key":"120","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","article-title":"Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models","volume":"19","author":"Nannini","year":"2013","journal-title":"Clin Canc Res"},{"issue":"2","key":"121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3322\/caac.20003","article-title":"Novel Agents on the Horizon for Cancer Therapy","volume":"59","author":"Adjei","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"122","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1078-0432.CCR-11-2105","article-title":"New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy","volume":"18","author":"Yao","year":"2012","journal-title":"Clin Cancer Res"},{"key":"123","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Koehl","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"124","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cbin.10179","article-title":"Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation","volume":"38","author":"Fang","year":"2014","journal-title":"Cell Biol Int"},{"key":"125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/bjc.2012.47","article-title":"Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum","volume":"106","author":"Park","year":"2012","journal-title":"Br J Cancer"},{"issue":"31","key":"126","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study","volume":"31","author":"Ferry","year":"2013","journal-title":"J Clin Oncol"},{"key":"127","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Pandolfi","year":"2008","journal-title":"J Clin Invest"},{"issue":"1","key":"128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1756283X12453636","article-title":"Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?","volume":"6","author":"Yau","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Kurzrock","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12885-015-1139-7","article-title":"Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression","volume":"15","author":"Kang","year":"2015","journal-title":"BMC Cancer"},{"key":"131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-5-29","article-title":"Mutations of PIK3CA in gastric adenocarcinoma","volume":"5","author":"Chan","year":"2005","journal-title":"BMC Cancer"},{"key":"132","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/ijc.21170","article-title":"AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer","volume":"117","author":"Oki","year":"2005","journal-title":"Int J Cancer"},{"issue":"1","key":"133","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/1471-2407-10-425","article-title":"LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells","volume":"10","author":"Kang","year":"2010","journal-title":"BMC Cancer"},{"issue":"18","key":"134","first-page":"4034","article-title":"Impact of PTEN\/AKT\/PI3K signal pathway on the chemotherapy for gastric cancer","volume":"24","author":"Tokunaga","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.23049","article-title":"Phosphoinositide 3-kinase\/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death","volume":"122","author":"Yu","year":"2008","journal-title":"Int J Cancer"},{"key":"136","doi-asserted-by":"crossref","unstructured":"Im, Lee, Nam. Tumori. 2005; 91:513\u2013521.","DOI":"10.1177\/030089160509100612"},{"issue":"1 Suppl","key":"137","first-page":"S21","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Tsao","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"1 Suppl","key":"138","first-page":"S37","article-title":"In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs","volume":"3","author":"Adjei","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"139","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors: targeting oncogene addiction and expedience","volume":"7","author":"Trusolino","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1242\/dev.024463","article-title":"Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology","volume":"136","author":"Cantley","year":"2009","journal-title":"Development"},{"issue":"10","key":"141","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2009.07.002","article-title":"Crosstalk in Met receptor oncogenesis","volume":"19","author":"Park","year":"2009","journal-title":"Trends Cell Biol"},{"issue":"4","key":"142","first-page":"817","article-title":"Hepatocyte growth factor and Met\/HGF receptors in patients with gastric adenocarcinoma","volume":"5","author":"P'eng","year":"1998","journal-title":"Oncol Rep"},{"issue":"3","key":"143","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000065477","article-title":"c-Met Expression in Gastric Cancer with Liver Metastasis","volume":"63","author":"Matsumoto","year":"2002","journal-title":"Oncology"},{"issue":"11","key":"144","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.0.CO;2-X","article-title":"The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor","volume":"82","author":"Watanabe","year":"1998","journal-title":"Cancer"},{"issue":"9","key":"145","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J","article-title":"The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas","volume":"85","author":"Nakano","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"146","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jso.23008","article-title":"Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma","volume":"106","author":"Zan","year":"2012","journal-title":"J Surg Oncol"},{"issue":"1","key":"147","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1023\/A:1013275706401","article-title":"p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis","volume":"47","author":"Manns","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"5","key":"148","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1080\/028418601750444204","article-title":"Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features","volume":"40","author":"Hsieh","year":"2001","journal-title":"Acta Oncol"},{"issue":"1","key":"149","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/cbt.12.1.15747","article-title":"RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma","volume":"12","author":"Grushko","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"150","first-page":"1111","article-title":"Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas","volume":"26","author":"Xin","year":"2011","journal-title":"Histol Histopathol"},{"issue":"6","key":"151","first-page":"1477","article-title":"The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation","volume":"19","author":"Monig","year":"2008","journal-title":"Oncol Rep"},{"issue":"1","key":"152","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18632\/oncotarget.718","article-title":"MET amplification as a potential therapeutic target in gastric cancer","volume":"4","author":"Yamada","year":"2013","journal-title":"Oncotarget"},{"issue":"10","key":"153","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.18632\/oncotarget.2003","article-title":"HGF\/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development","volume":"5","author":"Koeppen","year":"2014","journal-title":"Oncotarget"},{"issue":"9","key":"154","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1470-2045(14)70023-3","article-title":"Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study","volume":"15","author":"Loh","year":"2014","journal-title":"Lancet Oncol"},{"issue":"32","key":"155","doi-asserted-by":"crossref","first-page":"E2987","DOI":"10.1073\/pnas.1302725110","article-title":"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent","volume":"110","author":"Maun","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"156","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1158\/1078-0432.CCR-05-1418","article-title":"A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo","volume":"12","author":"Lamszus","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"157","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/1078-0432.CCR-13-2070","article-title":"Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies","volume":"20","author":"Moss","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5s","key":"158","article-title":"Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors","volume":"32","author":"Ramanathan","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"159","article-title":"Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC)","volume":"33","author":"Strickler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1634\/theoncologist.2010-0380","article-title":"Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers","volume":"16","author":"Garmey","year":"2011","journal-title":"The Oncologist"},{"issue":"2","key":"161","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10637-013-0057-2","article-title":"A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer","volume":"32","author":"Boku","year":"2014","journal-title":"Invest New Drugs"},{"issue":"suppl 3","key":"162","article-title":"Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer","volume":"33","author":"Hong","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5s","key":"163","article-title":"First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors","volume":"32","author":"Kwak","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"164","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s10637-011-9699-0","article-title":"Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks","volume":"30","author":"Minami","year":"2012","journal-title":"Invest New Drugs"},{"issue":"20","key":"165","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases","volume":"69","author":"Bentzien","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"166","doi-asserted-by":"crossref","first-page":"e54014","DOI":"10.1371\/journal.pone.0054014","article-title":"Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET\/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"167","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth","volume":"10","author":"Laird","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"168","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-11-1171","article-title":"Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer","volume":"18","author":"Yano","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"24","key":"169","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-14-0409","article-title":"A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors","volume":"20","author":"Ranson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc725","article-title":"RHO-GTPases and cancer","volume":"2","author":"Marshall","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"171","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1073\/pnas.1212324110","article-title":"Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors","volume":"110","author":"Zheng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"172","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: first global approval","volume":"74","author":"Garnock-Jones","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"173","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chembiol.2012.05.009","article-title":"Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases","volume":"19","author":"Zheng","year":"2012","journal-title":"Chem Biol"},{"issue":"8","key":"174","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Verstovsek","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6185","key":"175","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Gambin","year":"2014","journal-title":"Science"},{"issue":"4","key":"176","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Lee","year":"2005","journal-title":"Cancer Cell"},{"key":"177","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/asheducation-2009.1.636","article-title":"Therapeutic potential of JAK2 inhibitors","author":"Verstovsek","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"178","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.leu.2404948","article-title":"JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials","volume":"22","author":"Pardanani","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"179","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2013-0198","article-title":"AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors","volume":"18","author":"Eckhardt","year":"2013","journal-title":"Oncologist"},{"issue":"12","key":"180","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/ar.22820","article-title":"Involvement of nuclear JAK2 signaling in AG490-induced apoptosis of gastric cancer cells","volume":"296","author":"Si","year":"2013","journal-title":"Anat Rec"},{"issue":"5","key":"181","doi-asserted-by":"crossref","first-page":"e95993","DOI":"10.1371\/journal.pone.0095993","article-title":"Inhibition of the JAK2\/STAT3 pathway reduces gastric cancer growth in vitro and in vivo","volume":"9","author":"Giraud","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"182","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/cr.2011.109","article-title":"Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients","volume":"22","author":"Mo","year":"2012","journal-title":"Cell Res"},{"issue":"124","key":"183","first-page":"949","article-title":"Identification of CD44+ cancer stem cells in human gastric cancer","volume":"60","author":"Pang","year":"2013","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"184","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/ijo.2012.1720","article-title":"Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties","volume":"42","author":"Zhou","year":"2013","journal-title":"Int J Oncol"},{"issue":"6","key":"185","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3892\/ol.2013.1272","article-title":"CD44 gastric cancer cells with stemness properties are chemoradioresistant and highly invasive","volume":"5","author":"Wu","year":"2013","journal-title":"Oncol Lett"},{"issue":"7","key":"186","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00535-012-0712-y","article-title":"Cancer stem cells: the \u2018heartbeat\u2019 of gastric cancer","volume":"48","author":"Su","year":"2013","journal-title":"J Gastroenterol"},{"key":"187","first-page":"981261","article-title":"Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer","volume":"2014","author":"Luo","year":"2014","journal-title":"Biomed Res Int"},{"issue":"18","key":"188","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.3748\/wjg.v20.i18.5420","article-title":"Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment","volume":"20","author":"Nie","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"189","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1083\/jcb.201309141","article-title":"Coupling of Hedgehog and Hippo pathways promotes stem cell maintenance by stimulating proliferation","volume":"205","author":"Kalderon","year":"2014","journal-title":"J Cell Biol"},{"issue":"1","key":"190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10120-013-0254-x","article-title":"Gastric cancer stem cells: therapeutic targets","volume":"17","author":"Hattori","year":"2014","journal-title":"Gastric Cancer"},{"issue":"5","key":"191","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00535-009-0006-1","article-title":"The role of hedgehog signaling during gastric regeneration","volume":"44","author":"Oh","year":"2009","journal-title":"J Gastroenterol"},{"issue":"3","key":"192","doi-asserted-by":"crossref","first-page":"e17687","DOI":"10.1371\/journal.pone.0017687","article-title":"Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"193","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/jgh.12445","article-title":"Expression level of sonic hedgehog correlated with the speed of gastric mucosa regeneration in artificial gastric ulcers","volume":"29","author":"Kanda","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"194","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1758834010366430","article-title":"Targeting the Hedgehog pathway in cancer","volume":"2","author":"Lorusso","year":"2010","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"195","first-page":"1051","article-title":"Sonic hedgehog expression in gastric cancer and gastric adenoma","volume":"17","author":"Choi","year":"2007","journal-title":"Oncol Rep"},{"issue":"6","key":"196","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4291\/wjgp.v2.i6.103","article-title":"Role of Sonic Hedgehog signaling during progression from inflammation to cancer in the stomach","volume":"2","author":"Zavros","year":"2011","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"6","key":"197","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3892\/or_00000791","article-title":"Effect of Helicobacter pylori infection on the sonic hedgehog signaling pathway in gastric cancer cells","volume":"23","author":"Lee","year":"2010","journal-title":"Oncol Rep"},{"issue":"2","key":"198","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1349-7006.2009.01395.x","article-title":"Contrasting activity of Hedgehog and Wnt pathways according to gastric cancer cell differentiation: relevance of crosstalk mechanisms","volume":"101","author":"Lee","year":"2010","journal-title":"Cancer Sci"},{"issue":"1","key":"199","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2007.12.030","article-title":"Crosstalk of hedgehog and Wnt pathways in gastric cancer","volume":"263","author":"Katano","year":"2008","journal-title":"Cancer Lett"},{"issue":"8","key":"200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mc.20516","article-title":"Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer","volume":"48","author":"Omata","year":"2009","journal-title":"Mol Carcinog"},{"issue":"11","key":"201","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jjco\/hys137","article-title":"Prognostic value of sonic hedgehog protein expression in gastric cancer","volume":"42","author":"Hong","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"22","key":"202","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1158\/0008-5472.CAN-11-1338","article-title":"Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer","volume":"71","author":"Oh","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000336949","article-title":"Activation of the sonic hedgehog pathway and its prognostic impact in patients with gastric cancer","volume":"29","author":"Gotoh","year":"2012","journal-title":"Dig Surg"},{"issue":"8","key":"204","first-page":"5144","article-title":"Clinicopathological correlation and prognostic significance of sonic hedgehog protein overexpression in human gastric cancer","volume":"7","author":"Yu","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"205","first-page":"421","article-title":"Suppression of growth and migration by blocking the Hedgehog signaling pathway in gastric cancer cells","volume":"36","author":"Luo","year":"2013","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"206","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3892\/ol.2014.1964","article-title":"Characterization of sonic hedgehog inhibition in gastric carcinoma cells","volume":"7","author":"Du","year":"2014","journal-title":"Oncol Lett"},{"issue":"2","key":"207","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/biores.2014.0001","article-title":"Sonic hedgehog pathway contributes to gastric cancer cell growth and proliferation","volume":"3","author":"Cui","year":"2014","journal-title":"Biores Open Access"},{"issue":"15","key":"208","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-14-0011","article-title":"CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance","volume":"20","author":"Yoon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10 Suppl","key":"209","first-page":"s154","article-title":"Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas","volume":"12","author":"Miller","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"22","key":"210","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/1078-0432.CCR-13-1425","article-title":"Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study","volume":"19","author":"Curran","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"211","article-title":"A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study","volume":"31","author":"Wade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"212","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/1078-0432.CCR-12-1800","article-title":"A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer","volume":"19","author":"Low","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"213","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ctrv.2014.02.003","article-title":"Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer","volume":"40","author":"Adjei","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"214","first-page":"a007989","article-title":"Wnt signaling, stem cells, and cancer of the gastrointestinal tract","volume":"4","author":"Clevers","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"12","key":"215","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-09-2943","article-title":"Targeting Wnt signaling: can we safely eradicate cancer stem cells?","volume":"16","author":"Kahn","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"216","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc3419","article-title":"WNT signalling pathways as therapeutic targets in cancer","volume":"13","author":"Moon","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"217","doi-asserted-by":"crossref","first-page":"e1000676","DOI":"10.1371\/journal.pgen.1000676","article-title":"Oncogenic pathway combinations predict clinical prognosis in gastric cancer","volume":"5","author":"Rha","year":"2009","journal-title":"PLoS Genet"},{"key":"218","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1038\/cddis.2013.515","article-title":"Roles of Wnt\/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment","volume":"5","author":"Li","year":"2014","journal-title":"Cell Death Dis"},{"issue":"4","key":"219","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.28405","article-title":"The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer","volume":"134","author":"Podhajcer","year":"2014","journal-title":"Int J Cancer"},{"issue":"7","key":"220","first-page":"552","article-title":"Drug discovery approaches to target Wnt signaling in cancer stem cells","volume":"1","author":"Lorenzi","year":"2010","journal-title":"Oncotarget"},{"issue":"9","key":"221","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cas.12471","article-title":"Safely targeting cancer stem cells via selective catenin coactivator antagonism","volume":"105","author":"Kahn","year":"2014","journal-title":"Cancer Sci"},{"issue":"2","key":"222","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ceb.2013.01.004","article-title":"Wnt signaling in stem and cancer stem cells","volume":"25","author":"Birchmeier","year":"2013","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"223","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2013.03.035","article-title":"Gastric cancer stem cells: a novel therapeutic target","volume":"338","author":"Singh","year":"2013","journal-title":"Cancer Lett"},{"issue":"5","key":"224","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/stem.30","article-title":"Identification of gastric cancer stem cells using the cell surface marker CD44","volume":"27","author":"Wang","year":"2009","journal-title":"Stem Cells"},{"issue":"11","key":"225","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00432-011-1038-5","article-title":"Identification of CD44+CD24+ gastric cancer stem cells","volume":"137","author":"Yang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"226","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2011.06.003","article-title":"Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype","volume":"310","author":"Bian","year":"2011","journal-title":"Cancer Lett"},{"issue":"21","key":"227","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1007\/s00018-011-0672-z","article-title":"Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research","volume":"68","author":"Oh","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"228","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1078-0432.CCR-10-1204","article-title":"Targeting Wnt signaling in colon cancer stem cells","volume":"17","author":"Medema","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"229","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/ncb2048","article-title":"Wnt activity defines colon cancer stem cells and is regulated by the microenvironment","volume":"12","author":"Medema","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"7","key":"230","doi-asserted-by":"crossref","first-page":"e67811","DOI":"10.1371\/journal.pone.0067811","article-title":"Wnt pathway activity in breast cancer sub-types and stem-like cells","volume":"8","author":"Clarke","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"231","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.3390\/ijms14046624","article-title":"Regulation of ovarian cancer stem cells or tumor-initiating cells","volume":"14","author":"Shin","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"17","key":"232","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2174\/13816128112092464","article-title":"Role of Wnt\/beta-catenin signaling in drug resistance of pancreatic cancer","volume":"18","author":"Xie","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"3","key":"233","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2010.01.028","article-title":"Wnt\/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells","volume":"392","author":"Ma","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"234","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1007\/s00018-007-7164-1","article-title":"Notch and cancer: a double-edged sword","volume":"64","author":"Radtke","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"235","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan R","year":"2009","journal-title":"Cell"},{"issue":"6","key":"236","first-page":"2223","article-title":"Recent insights into the role of Notch signaling in tumorigenesis","volume":"107","author":"Karsan","year":"2005","journal-title":"Blood"},{"issue":"4","key":"237","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2559.2012.04274.x","article-title":"Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression","volume":"61","author":"Kim","year":"2012","journal-title":"Histopathology"},{"issue":"1","key":"238","first-page":"1","article-title":"Role of Notch signaling pathway in gastric cancer pathogenesis","volume":"17","author":"Wojnicz","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"issue":"27","key":"239","first-page":"9191","article-title":"Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature","volume":"20","author":"Zhou","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"12","key":"240","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1158\/0008-5472.CAN-08-4021","article-title":"The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2","volume":"69","author":"Chi","year":"2009","journal-title":"Cancer Res"},{"issue":"12","key":"241","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1600-0463.2007.00751.x","article-title":"Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias","volume":"115","author":"Lee","year":"2007","journal-title":"APMIS"},{"issue":"4","key":"242","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/1078-0432.CCR-05-2570","article-title":"Notch signaling","volume":"12","author":"Miele","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"38","key":"243","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1038\/onc.2008.226","article-title":"Rational targeting of Notch signaling in cancer","volume":"27","author":"Miele","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"244","first-page":"258","article-title":"Targeting Notch signaling pathway to overcome drug resistance for cancer therapy","volume":"1806","author":"Sarkar","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"245","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","article-title":"Notch Signaling, \u03b3-Secretase Inhibitors, and Cancer Therapy","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"246","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrd4161","article-title":"The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment","volume":"13","author":"Halder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"247","first-page":"103","article-title":"The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway","volume":"37","author":"Anders","year":"2006","journal-title":"Int J Gastrointest Cancer"},{"issue":"4","key":"248","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/039463201202500415","article-title":"Clinicopathologic characteristics of YES-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer","volume":"25","author":"Chen","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"9","key":"249","first-page":"3827","article-title":"Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer","volume":"32","author":"Kim","year":"2012","journal-title":"Anticancer Res"},{"key":"250","first-page":"1611","article-title":"A breakdown of the Hippo pathway in gastric cancer","volume":"58","author":"Wang","year":"2011","journal-title":"Hepatogastroenterology"},{"issue":"12","key":"251","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Pan","year":"2012","journal-title":"Genes Dev"},{"issue":"10","key":"252","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2013.08.006","article-title":"Regulation of the Hippo pathway and implications for anticancer drug development","volume":"34","author":"Guan","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"253","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/bjc.2014.95","article-title":"Phase I\/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer","volume":"110","author":"Pereira","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"254","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"255","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.bjc.6604885","article-title":"Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients","volume":"100","author":"Teixeira","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"256","first-page":"65","article-title":"Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer","volume":"15","author":"Ochiai","year":"2006","journal-title":"Oncol Rep"},{"key":"257","first-page":"941259","article-title":"HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients","volume":"2012","author":"Matkowski","year":"2012","journal-title":"Scientific World Journal"},{"issue":"1","key":"258","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1756-9966-28-152","article-title":"The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray","volume":"28","author":"Du","year":"2009","journal-title":"J Exp Clin Canc Res"},{"issue":"10","key":"259","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/carcin\/bgi130","article-title":"Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas","volume":"26","author":"Xie","year":"2005","journal-title":"Carcinogenesis"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T13:34:02Z","timestamp":1692020042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,22]]},"references-count":259,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2015,9,22]]}},"alternative-id":["4990","26267324"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4990","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,22]]}}}